An update from the latest workshop on asymptomatic primary hyperparathyroidism

Otolaryngologic Clinics of North America

Volumn 37, Issue 4, 2004, Pages 737-749

  Lendel, Irina ^a,b   Horwith, Melvin ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; ESTROGEN; PARATHYROID HORMONE; RALOXIFENE;

ALBRIGHT SYNDROME; ANXIETY; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CARDIOVASCULAR MALFORMATION; CLINICAL TRIAL; COGNITIVE DEFECT; CREATININE CLEARANCE; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; HIP; HUMAN; HYPERCALCEMIA; IMMUNORADIOMETRIC ASSAY; INCIDENCE; LUMBAR SPINE; MENTAL DISEASE; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROLITHIASIS; PANCREATITIS; PARATHYROIDECTOMY; PEPTIC ULCER; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; RADIUS; REVIEW; THROMBOEMBOLISM; URINARY EXCRETION;

BONE DENSITY; CALCIUM; CONSENSUS DEVELOPMENT CONFERENCES, NIH; CREATININE; HUMANS; HYPERPARATHYROIDISM; NATIONAL INSTITUTES OF HEALTH (U.S.); PRACTICE GUIDELINES; UNITED STATES;

EID: 3242705935     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2004.02.006     Document Type: Review

References (66)

1. Heath H. III, Hodgson S., Kennedy M. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact on a community. N Engl J Med. 302:1980;189-193
2. Silverberg S. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin N Am. 29:(3):2000;451-464
3. Bilezikian J., Potts J. Asymptomatic primary hyperparathyroidism: new issues and new questions - bridging the past with the future. J Bone Miner Res. 17:(Suppl 2):2002;N57-N67
4. Davies M., Fraser W., Hoskin D. The management of primary hyperparathyroidism. Clinic Endocrinol. 57:2002;145-155
5. Silverberg S., Bilezikian J. Extensive personal experience: evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab. 81:(6):1996;2036-2040
6. Silverberg S., Shane E., Jacobs T., Siris E., Bilezikian J. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 341:1999;1249-1255
7. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference statement. Ann Intern Med. 114:(7):1991;593-597
8. st century. J Clin Endocrinol Metab. 87:(12):2002;5353-5361
9. Kearns A., Thompson G. Medical and surgical management of hyperparathyroidism. Mayo Clin Proc. 77:2002;87-91
10. Talpos G., Bone H., Kleerekoper M., Phillips E., Alam M., Honasoge M., et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery. 128:2000;1013-1021
11. Sywak M., Knowlton S., Pasieka J., Parsons L., Jones J. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyperparathyroidism. Surgery. 132:2002;1013-1020
12. Chan A., Duh Q., Katz M., Siperstein A., Clark O. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg. 222:(3):1995;402-414
13. Pasieka J., Parsons L., Demeure M., Wilson S., Malycha P., Jones J., et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 26:2002;942-949
14. Silverberg S., Bilezikian J. Incipient primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 88:2003;5348-5352
15. Siperstein A., Shen W., Chan A., Duh Q., Clark O. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg. 127:1992;1157-1163
16. Palmer M., Bergstrom R., Akerstrom G., Adami H., Jakobsson S., Ljunghall S. Survival and renal function in untreated hypercalcemia. Population-based cohort study with 14 years of follow up. Lancet. 1:(8524):1987;59-62
17. Hedback G., Oden A., Tisell L. The influence of surgery on the risk of death in patients with primary hyperparathyroidism. World J Surg. 15:1991;399-407
18. Hedback G., Tisell L., Bengtsson B., Hedman I., Oden A. Premature death in patients operated on for primary hyperparathyroidism. World J Surg. 28:1998;271-276
19. Hedback G., Oden A. Increased risk of death from primary hyperparathyroidism - an update. Eur J Clin Invest. 28:(4):1998;271-276
20. Ljunghall S., Jakobsson S., Joborn C., Palmer M., Rastad J., Akerstrom G. Longitudinal studies of mild primary hyperparathyroidism. J Bone Miner Res. 6:(Suppl 2):1991;S111-S116
21. Heath D., Heath E. Conservative management of primary hyperparathyroidism. J Bone Miner Res. 6:(Suppl 2):1991;S117-S120
22. Wermers R., Khosla S., Atkinson E., Grant C., Hodgson S., O'Fallon M., et al. Survival after the diagnosis of hyperparathyroidism: a population -based study. Am J Med. 104:1998;115-122
23. Leifsson B., Ahren B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab. 81:1996;2149-2153
24. Miller P., Bilezikian J. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N98-N102
25. Silverberg S., Bilezikian J. Primary hyperparathyroidism: still evolving? J Bone Miner Res. 12:(5):1997;856-862
26. Bilezikian J., Silverberg J., Shane E., Parisien M., Dempster D. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res. 6:(Suppl 2):1991;S85-S89
27. Silverberg S., Locker F., Bilezikian J. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1996;4007-4012
28. Silverberg S., Gartenberg F., Jacobs T., Shane E., Siris E., Staron R., et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1995;729-734
29. Christiansen P., Steiniche T., Brixen K., Hessov I., Melson F., Heickendorff L., et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone. 25:1999;589-595
30. Guo C., Thomas W., Al-Dehaimi A., Assiri A., Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1996;3487-3491
31. Abdelhadi M., Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 83:1998;3845-3851
32. Vestergaard P., Mollerup C., Frokjar V., Christiansen P., Blichert-Toft M., Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 321:2000;598-602
33. Khosla S., Melton J. III, Wermers R., Crowson C., O'Fallon M., Riggs L. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 14:1999;1700-1707
34. Melton J. III, Atkinson E., O'Fallon M., Health H. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med. 152:1992;2269-2273
35. Silverberg S., Gartenberg F., Jacobs T., Shane E., Siris E., Staron R. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab. 80:1995;723-729
36. Woitge H., Pecherstorfer M., Li Y., Keck A., Horn E., Ziegler R. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res. 14:1999;792-801
37. Silverberg S., Brown I., Bilezikian J. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med. 113:2002;681-684
38. Silverberg S. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 17:2002;N117-N125
39. Stefenelli T., Abela C., Frank H., Koller-Strametz J., Globits S., Bergler-Klein J., et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow up. J Clin Endocrinol Metab. 82:1997;106-112
40. Piovesan A., Molineri N., Casasso F., Emmolo I., Ugliengo G., Cesario F., et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clinic Endocrinol. 50:1999;321-328
41. Joborn C., Hetta J., Lind L., Rastad J., Akerstrom G., Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia. Surgery. 105:1989;72-78
42. McAllion S., Paterson C. Psychiatric morbidity in primary hyperparathyroidism. Postgrad Med J. 65:1989;628-631
43. Kleerekoper M., Bilezikian J. A cure in search of a disease: parathyroidectomy for nontraditional features of primary hyperparathyroidism. Am J Med. 96:(2):1994;99-100
44. Paloyan D., Simonowitz D., Paloyan E., Snyder T. Pancreatitis associated with primary hyperparathyroidism. Am Surg. 48:(8):1982;366-368
45. Khan A., Bilezikian J., Kung A., Ahmed M., Dubois S., Ho A., et al. A double blind randomized placebo-controlled trial of alendronate in primary hyperparathyroidism. J Bone Miner Res. 16:(Suppl 1):2001;S226
46. Rubin M., Lee K., Silverberg S. Raloxifene lowers calcium and markers of bone turnover in primary hyperparathyroidism. J Bone Miner Res. 16:(Suppl 1):2001;S420
47. Silverberg S., Bone H. III, Marriott T., Locker F., Thys-Jacobs S., Dziem G., et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med. 337:1997;1506-1510
48. Nemeth E., Steffey M., Hammerland L., Hung B., Van Wagenen B., DelMar E., et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A. 95:1998;4040-4045
49. Grey A., Stapleton J., Evans M., Tatnell M., Reid I. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. Ann Intern Med. 125:1996;360-368
50. Reeve T., Babidge W., Parkyn R., Edis A., Delbridge L., Devitt P., et al. Minimally invasive surgery for primary hyperparathyroidism. Systematic review. Arch Surg. 135:2000;481-487
51. Levin K., Clark O. The reasons for failure in parathyroid operations. Arch Surg. 124:1989;911-915
52. Vogel M., Lucas R., Czako P. Unilateral parathyroid exploration. Am Surg. 64:1998;693-697
53. Gauger P., Reeve T., Delbridge L. Endoscopically assisted, minimally invasive parathyroidectomy. Br J Surg. 86:1999;1563-1566
54. Delbridge L., Dolan S., Thi Hop T., Robinson B., Wilkinson M., Reeve T. Minimally invasive parathyroidectomy: 50 consecutive cases. MJA. 172:2000;418-422
55. Goldstein R., Blevins L., Delbeke D., Martin W. Effect of minimally invasive radioguided parathyroidectomy on efficacy, length of stay, and costs in the management of primary hyperparathyroidism. Ann Surg. 231:2000;732-742
56. Denham D., Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg. 186:1998;293-304
57. Borley N., Collins R., O'Doherty M., Coakley A. Technetium-99m sestamibi parathyroid localization is accurate enough for scan-directed unilateral neck exploration. Br J Surg. 83:1996;989-991
58. Doppman J., Miller D. Localization of parathyroid tumors in patients with asymptomatic hyperparathyroidism and no previous surgery. J Bone Miner Res. 6:(Suppl 2):1991;S153-S158
59. Neumann D., Esselstyn C., Madera A., Wong O., Lieber M. Parathyroid detection in secondary hyperparathyroidism with I123/Tc-sestamibi subtraction single photon emission computed tomography. J Clin Endocrinol Metab. 83:1998;3867-3871
60. Allendorf J., Kim L., Chabot J., DiGiorgi M., Spanknebel K., Logerfo P. The impact of sestamibi scanning on the outcome of parathyroid surgery. J Clin Endocrin Metab. 88:2003;3015-3018
61. Salti G., Fedorak I., Yashiro T., Fulton N., Hara H., Yousefzadeh D., et al. Continuing evolution in the operative management of primary hyperparathyroidism. Arch Surg. 127:1992;831-837
62. Greene A., Mowschenson P., Hodin R. Is sestamibi-guided parathyroidectomy really cost-effective? Surgery. 126:1999;1036-1041
63. Shen W., Sabanci U., Morita E., Siperstein A., Duh Q., Clark O. Sestamibi scanning is inadequate for directing unilateral neck exploration for first-time parathyroidectomy. Arch Surg. 132:1997;969-976
64. Ruda J., Stack B.C. Jr., Hollenbeak C. The cost-effectiveness of sestamibi scanning compared to bilateral neck exploration for the treatment of primary hyperparathyroidism. Otolaryngol Clin North Am. 37:2004;855-870
65. Garner S., Leight G. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery. 126:1999;1132-1138
66. Miura D., Wada N., Arici C., Morita E., Duh Q., Clark O. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg. 26:2002;926-930